DEERFIELD, IL--(BUSINESS WIRE)--Ron K. Labrum, the incoming CEO of the new transfusion therapies company that will be formed following its acquisition from Baxter International Inc., today announced that Hiroshi Uchida and four additional senior executives will join the new company. The five executives will assume their roles when the business becomes a stand-alone entity, which is expected to happen in the first quarter of 2007. In October, it was announced that Texas Pacific Group (TPG) and Maverick Capital, Ltd. will acquire the transfusion therapies business from Baxter International Inc. and establish the business as an independent company.
